X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
IMCY-0141 is the Imotope™ is designed based on myelin oligodendrocyte glycoprotein with the aim to halt the progression of multiple sclerosis (MS) by stopping the body's immune system from attacking the central nervous system.
Lead Product(s): IMCY-0141
Therapeutic Area: Neurology Product Name: IMCY-0141
Highest Development Status: Phase I/ Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 13, 2023
Details:
IMCY-0098, a synthetic peptide based on insulin, is designed to halt the progression of diabetes by stopping the body’s immune system from attacking beta cells. With early intervention, the pancreas’ ability to produce insulin may be preserved to manage the disease.
Lead Product(s): IMCY-0098
Therapeutic Area: Endocrinology Product Name: IMCY-0098
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 01, 2023
Details:
Positive interim biomarker Phase 2 IMPACT Type 1 Diabetes Study data support specific immune signature induced by Imotope (IMCY-0098) and effect on potentially pathogenic T cells.
Lead Product(s): IMCY-0098
Therapeutic Area: Endocrinology Product Name: Imotope
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 13, 2022
Details:
The funding will allow the company advance its lead Imotope candidate for Type 1 Diabetes into phase 2 as well as four other programs in Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorders, Celiac Disease, and Rheumatoid Arthritis.
Lead Product(s): Imotope
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Peptide
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: $25.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing February 17, 2021
Details:
Imcyse and Pfizer will collaborate to develop Imotope™ candidates to potentially treat Rheumatoid Arthritis. Pfizer will lead clinical development and commercialization activities.
Lead Product(s): Undisclosed
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Peptide
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: $180.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration February 03, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
